Direct costs for diabetes management constitute a substantial component of financial toxicity and include expenses for medications (particularly insulin), glucose monitoring supplies, devices, and healthcare services for routine disease management and treating complications (Fig. 2). The gene discussed is INS; the disease is diabetes mellitus.